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Background: microRNAs (miRNAs) are emerging as key regulators of the immune system, but their role in CD8+ T
cell differentiation is not well explored. Some evidence suggests that signals from cell surface receptors influence
the expression of miRNAs in CD8+ T cells, and may have consequent effects on cell phenotype and function. We set
out to investigate whether common gamma chain cytokines modulated human CD8+ T cell expression of miR-146a,
which previous studies have associated with different stages of CD8+ differentiation. We also investigated how changes
in miR-146a related to other miRNAs that alter with CD8+ differentiation status.
Methods: We treated human CD8+ T cells with the cytokines IL-2, IL-7 or IL-15 either at rest or after stimulation with
anti-CD3 and anti-CD28. For some experiments we also purified human CD8+ T cell subsets ex vivo. Flow cytometry
was used in parallel to assess cell surface memory marker expression. Total RNA from these cells was subjected to
microarray analysis and real-time PCR for miRNA expression. Nucleofection studies were performed to assess potential
mRNA targets of miR-146a.
Results: We find that miR-146a is up-regulated in naïve CD8+ T cells exposed to IL-2 or IL-15, even in the absence of
an activating T cell receptor stimulus, but not when IL-7 is also present. miR-146a expression correlates with a memory
phenotype in both ex vivo and in vitro cultured cells although in our hands overexpression of miR-146a was not
sufficient alone to drive a full memory phenotype. In ex vivo analysis, miR-146a was one of a small number of
miRNAs that was differentially expressed between naïve and memory CD8+ T cells.
Conclusions: miR-146a is emerging as a critical regulator of immune system. Our data shows that miR-146a
expression is strongly influenced by the cytokine milieu even in the absence of a T cell receptor stimulus. Our
results have implications for studies designed to assess the function of miR-146a, help to define a fingerprint
of miRNA expression in CD8+ T cell subsets and may be useful when designing optimal protocols for T cell
expansion as efficacy of T cell immunotherapy is correlated with an ‘early’ memory phenotype.
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During an acute intracellular bacterial or viral infection
antigen specific CD8+ T cells rapidly proliferate and
expand into effector T cells which clear the pathogen.
Depending on the strength of stimulating signals received
the cells differentiate into specific subsets of memory
cells (for a recent review see [1]). The expression of cell
surface makers allows these subsets to be identified
using polychromatic flow cytometry [2]. Although the
exact lineage of the relationship between these subsets
remains controversial [3] they can be classified along a
progressive path of differentiation based on their pheno-
type, function, expression of specific transcription factors
and more recently their miRNA profile [1,2,4]. However,
the molecular circuitry that underlies this differentiation
process has only recently begun to be elucidated.
miRNAs are small, 21–23 nucleotide long single-
stranded molecules of RNA that function to inhibit gene
expression post-transcriptionally [5]. They bind by partial
base-pair complementarity primarily to the 3′ UTR of
messenger RNAs as part of the RNA induced silencing
complex (RISC). It has been predicted that up to 90%
of the human transcriptome is regulated by miRNAs
[6]. Furthermore it has been proposed that they function
to fine tune gene expression [7]. Therefore it is not sur-
prising that the complex system of T cell development
which requires careful regulation to achieve immune
homeostasis is subject to control by miRNAs, as reviewed
by Jeker and Bluestone [4]. An early indication of their
involvement in this process was provided by experiments
in mice with a conditional deletion of Dicer, a key enzyme
in microRNA biogenesis, in the T cell lineage. Impaired
peripheral CD8+ T cell development was observed [8].
More recently deletion of Dicer in mature CD8+ T cells
in a mouse model suggested a role for miRNAs in the
activation, migration and survival of these cells [9].
Roles are also emerging for miRNAs in the differenti-
ation in human CD8+ T cells [10-12]. Such functions for
miRNAs have particular relevance to adoptive transfer
of T cells for cancer therapy or immune reconstitution
following bone marrow and haematopoietic stem cell
transplantation. Experiments in mice indicate that the
use of less differentiated T cells yields better anti-tumour
properties compared to their more differentiated counter-
parts [13-16]. Clinical grade protocols designed to obtain
and maintain these optimum cells are still being defined
although it is clear that cytokines used in culture can
affect the differentiation status of cells [17]. Typically
T cells are cultured in IL-2 which tends to drive cells
to a more differentiated phenotype [11,18]. Conversely
cytokines such as IL-7 and IL-15 appear to conserve or
promote a less differentiated phenotype [19,20]. We set
out to understand whether human CD8+ T cells cultured
in such cytokines showed changes in specific miRNAmolecules that have already been linked to differentiation
status. Our hypothesis was that expression of specific
miRNAs might vary under different cytokine culture re-
gimes, and that this expression might correlate with – and
potentially be responsible for – changes in cell surface
phenotype and function. If so, miRNA expression might
be informative to the design of protocols used to expand
T cells in vitro for use in immunotherapy. In addition a
memory subset specific miRNA profile could aid identifi-
cation of the prime T cells for therapeutic use and poten-
tially identify miRNAs that could be used to genetically
modify T cells in vitro for use in adoptive immunotherapy.
Methods
Cell cultures and stimulation
Peripheral blood mononuclear cells (PBMCs) were har-
vested from healthy donors after informed consent in
accordance with methods approved by the local ethics
committee (University of Auckland Ethics Committee,
NZ). PBMCs were isolated by gradient separation using
Lymphoprep™ (Axis-Shield). CD8+ cells were enriched
from PBMCs using the CD8+ T Cell Isolation Kit (Mil-
tenyiBiotech) following manufacturer’s instructions. For
initial microarray experiments cells were then labelled
with anti-CD4-PE, anti-CD45RO-PECy7 and anti-CD28-
APC (all from BD Biosciences), anti- CD45RA-PE-TR
(Invitrogen), anti-CD8-APC Cy7 (Biolegend) and anti-
CCR7 FITC (R&D) fluorescent antibodies. They were
then FACS-purified into naïve (CD8+, CCR7+, CD45RA+,
CD45RO-), central memory (CD8+, CCR7+, CD45RA-,
CD45RO+) and effector memory subsets (CD8+, CCR7-,
CD45RA-, CD45RO+) on FACS Aria™ II (BD Biosciences).
Post-sorting analysis of purified subsets revealed greater
than 98% purity. Cell surface memory phenotyping was
performed using the antibodies listed above and CD62L-
PerCpCy5.5 (Biolegend).
For subsequent validation experiments CD3+ or CD8+
cells were enriched from PBMCs using the Pan T Cell
Isolation Kit II or CD8 Isolation Kit respectively (Milte-
nyiBiotech) following manufacturer’s instructions. To
further enrich for the naïve cell fraction (CD45RO-)
CD45RO microbeads were used (MiltenyiBiotech). For
expansion experiments T cells were activated with anti-
CD3/CD28-conjugated magnetic beads (Expander Beads,
Invitrogen) in 1:1 bead/T-cell ratio in RPMI medium
supplemented with 5% human serum and IL-2 and IL-
12 at 10 ng/ml. After 48 hours beads were removed and
cells were grown in either IL-2 at 10 ng/ml, IL-7 at
10 ng/ml or IL-15 at 10 ng/ml or concentrations as
stated in the text. For culture in cytokine in the absence
of a TCR stimulus naïve cells were rested in RS5 with
either IL-2 or IL-15 +/− IL-7 or IL-7 alone. All cytokines
were supplied by Peprotech. Cytokines and medium
were replaced every 3–4 days.
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FACS sorted cells were washed once in ice-cold PBS
and total RNA was purified using the miRVANA kit
(Ambion). RNA integrity was assessed using a bioanaly-
ser (Agilent). 500 ngs of RNA were reverse trans-
cribed and labelled using the Flash Tag Biotin HSR kit
(Genisphere) and hybridised to Gene Chip miRNA
Arrays 1.0 (Affymetrix) according to manufacturer’s pro-
tocols. Fluorescent signals were recorded by an Affyme-
trix scanner 3000 using Gene Chip Operating Software.
The statistical software program R was used to analyse
the results. The data was pre-processed and normalised
using RMA from the R package [21]. The R package
limma was used to check for differential expression, and
an empirical Bayes method was used to moderate the t-
statistic. In order to adjust for multiple testing, the
Benjamini-Hochberg method was used to correct the p-
values, and adjusted p-values are reported in the text.
The human subset of the results was extracted and all
subsequent plots were made on the human transcripts.
Microarray data has been deposited in the Gene Ex-
pression Omnibus (GEO) database and can be accessed
via accession no. GSE54867.
qRT-PCR
Total RNA was purified using the miRVANA kit
(Ambion) or where stated with RNA-GEM Tissue Plus
(ZyGem). To analyse the expression of specific miRNAs
individual cDNAs were prepared from 10 ngs miR-
VANA RNA using the Taqman miRNA RT kit (ABI)
and specific Taqman small RNA primers (ABI) accord-
ing to manufacturer’s instruction. Real-time PCR reac-
tions were prepared with Taqman FAST mastermix and
run on an ABI Prism HT 7900 machine (Applied Bio-
systems). RNU44 was used as an internal control and
relative expression was calculated as ΔΔCt. To analyse
the expression of specific mRNAs total cDNA was pre-
pared using the Superscript first strand synthesis cDNA
kit (Invitrogen). Real-time PCR reactions were prepared
using 10 ngs total cDNA with Taqman probes (ABI) and
run as above. HPRT and B2M were used as internal
control genes and relative expression was calculated as
ΔΔCt. RNA-GEM Tissue Plus was used according to
manufacturer’s instructions. 500,000 cells were lysed in
50 uls lysis solution. 2uls of the resulting lysate was used
directly in cDNA synthesis reactions for miRNA and
total cDNA.
Nucleofection
Cells were electroporated using the Amaxa Human T Cell
Nucleofector® Kit (Lonza) according to manufacturer’s
instructions for unstimulated human T cells. Per transfec-
tion, 5 million cells were combined with 300nM siRNA or
miRNA mimic (miRVANA miRNA mimic, Ambion) andpulsed in a Nucleofector II device using program V-024.
Equivalent amounts of fluorescently labelled Block iT
siRNA (Invitrogen) was used to assess electroporation effi-
ciency in separate control samples. After 48 hours total
RNA was purified using the miRVANA kit (Ambion).
Analysis of CD45 isoforms by PCR
Total RNA was purified using the miRVANA kit (Ambion)
and CD45 isoform expression was assessed by PCR as
described by ten Dam et al. [22]. In brief, first strand cDNA
was prepared using primer LCA9 (5′-GTAATCCACAGT
GATGTTTGC-3′) with 250 ng total RNA and the Super-
script first strand synthesis cDNA kit (Invitrogen). cDNA
was then amplified using primers LCA2 (5′-ATTGGA
TCCGCTGACTTCCAGATATGACC-3′) and LCA7 (5′-
CCGAGATCTTCAGAGGCATTAAGGTAGGC-3′). PCR
products were visualised on a 2% agarose gel.
Results
Differential memory phenotype and miR-146a expression
in CD8+ T cells expanded in different cytokines
To investigate the effects of different cytokines on T cell
phenotype and miRNA expression, we first developed a
system in which T cells could be cultured with or with-
out exogenous IL-2. We took naïve CD8+ T cells and
stimulated them with CD3/28 beads and expanded them
either in the presence of IL-7 or IL-2 alone for 28 days.
We then assessed the cell surface phenotype of our
in vitro stimulated cells to establish if culture in IL-2
versus IL-7 caused a modulation of receptors associated
with T cell survival and effector function. Human CD8+
T cells can be assigned into at least four subsets based
on their expression of specific cell-surface markers
which correlate with their differentiation status. These
subsets and markers include naïve (N =CCR7+, CD45RA+,
CD45RO-, CD28+, CD62L+), central memory (Tcm =
CCR7+, CD45RA-, CD45RO+, CD28+, CD62L+), effector
memory (Tem=CCR7-, CD45RA-, CD45RO+, CD28+,
CD62L-) and effector memory CD45RA+ cells (TemRA=
CCR7-, CD45RA+, CD45RO-, CD28-, CD62L-). As is
shown in Figure 1A-B we observed a significantly lower
proportion of CCR7+ and CCR7 + CD45RO- cells (i.e.
indicative of a naïve-like phenotype) being retained fol-
lowing CD3/CD28 bead stimulation and culture for
28 days in IL-2 versus IL-7.
In order to assess miRNA expression we prepared
RNA from cells exposed to IL-2 and IL-7 for 28 days
as above and subjected it to microarray analysis using
GeneChip miRNA Arrays 1.0 (Affymetrix). The arrays
contain 46,228 probe sets representing over 6703 miR-
NAs. We confined our analysis to the 847 human miRNAs
represented on the chip. A normalised log2 fluorescence
value of 4.0 was set as our arbitrary cut off for expression



























































Cytokine for 28 days
Figure 1 miR-146a expression correlates with a memory phenotype and exposure to IL-2 in naïve T cells. Naïve CD8+ T cells were stimulated
with anti-CD3/28 magnetic beads and cultured in the presence of either 10 ng/ml IL-2 or IL-7. At 28 days post stimulation cells were harvested and
either subjected to FACS analysis to assess expression levels of T cell memory markers CD45RO and CCR7 or assessed for miR-146a expression levels
by RT-PCR. (A) Graph showing % positive cells for CCR7+ and (B) CCR7 + CD45RO- as assessed by FACS analysis. Each data point represents one donor,
n = 4. Statistical significance was analysed using GraphPad Prism software using the Student’s t-test. (C) RT-PCR relative expression data for miR-146a at
day 28 post stimulation for the cells phenotyped in panels A and B. Each data point represents the average of triplicates from an individual donor,
n = 4. Statistical significance was analysed using GraphPad Prism software on non-normalised expression data using the Student’s t-test. Results with a
p value <0.05 were considered to be statistically significant. * = p <0.05; ** = p <0.01. (D) Naïve T cells were stimulated as in panel C in the presence of
10 ng/ml IL-2. At various time points post-stimulation cells were harvested and miR-146a expression levels were assessed by RT-PCR. (E) As (D) but cells
were grown in the presence of 10 ng/ml IL-7. Each data point represents the average of triplicates from an individual donor. The data in panels D and
E represent collated data from 4 donors (5 donors for IL-7) each tested at between 1 – 4 time points.
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affected by the different culture conditions, miR-146a
showed an average fold difference in expression of >124
(data not shown). This result was validated using RT-PCR
(using the same cells phenotyped in Figure 1A-B) and the
positive relationship between miR-146a expression and
IL-2 exposure is shown in Figure 1C. A time-course was
performed to establish at what point miR-146a expression
was induced. The differential expression in IL-2 vs IL-7
became apparent between 13–23 days post-stimulation
and tended to increase in the presence of IL-2 over time
(Figure 1D and E).
miR-146a expression is up-regulated in the presence of
IL-2 but not IL-7, even in the absence of a TCR stimulus
As described above, miR-146a was up-regulated in human
CD8+ cells stimulated and cultured in the presence of IL-
2, consistent with previous report in human CD4+ cells
[23,24], Jurkat cells [24] and mouse CD8+ cells [23,25].However it was not clear whether the up-regulation
required a TCR signal, or was dependent upon exposure
to IL-2, or both. We therefore next asked if IL-2 alone
was sufficient to drive the expression of this miRNA.
Naïve cells were isolated and rested for up to 28 days in
IL-2. As shown in Figure 2 miR-146a was up-regulated by
IL-2 alone, in the absence of an exogenous TCR stimulus.
Levels of expression were in a similar range to those
observed in the presence of IL-2 with a TCR stimulus (cf.
Figures 2 to 1C and D).
miR-146a expression is up-regulated by IL-2 or IL-15 but
inhibited if IL-7 is also present
The IL-2 receptor is made up of 3 subunits: alpha
(CD25), beta (CD122) and gamma (CD132). The gamma
chain is common to the receptors of 6 cytokines includ-
ing IL-2, IL-15 and IL-7, the beta chain is shared only by
IL-2 and IL-15 whilst the alpha chain is unique to IL-2












Days in IL-2 alone
Figure 2 miR-146a is up-regulated by IL-2 exposure alone
without an activating TCR stimulation. Naïve cells were not
stimulated, but following purification were cultured in the presence of
10 ng/ml IL-2. At various time points cells were harvested and miR-146a
expression levels were assessed by RT-PCR. Each data point represents
the average of triplicates from an individual donor. The data represents
collated data from 4 donors each tested at between 1 – 4 time points.
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next asked if IL-15 could also induce expression of miR-
146a in the same way as IL-2. As is shown in Figure 3A
naïve cells exposed to IL-15 for 28 days express high
levels of miR-146a comparable to cells exposed to IL-2
alone, and in both cases significantly higher levels than
in cells exposed to IL-7 alone, where expression is neg-
ligible. Interestingly when cells are cultured in IL-2 or
IL-15 plus IL-7 there is no significant up-regulation of
miR-146a, suggesting that the presence of IL-7 inhibits
expression of this miRNA. This finding is consistent
with the data in Figure 1, where the major difference
















































Figure 3 miR-146a expression is up-regulated by IL-2 or IL-15 but inh
presence of IL-7, IL-2, IL-7 and IL-2, IL-15 or IL-7 and IL-15, all at 10 ng/ml. 2
levels by RT-PCR. Each data point represents the average of triplicates from
using GraphPad Prism software using one way ANOVA test (on paired data
p value <0.05 were considered to be statistically significant. *** = p <0.001. (B
CD62L + as assessed by FACS analysis. Each data point represents data from owith an up-regulation of miR-146a we also observed move-
ment towards a cell-surface memory phenotype with a
decrease in the percentage of CCR7 +CD45RA+, CD28+
and CD62L + cells (Figure 3B-D).
Antigen exposure in vivo strongly upregulates miRNA-146a
in human CD8+ T cells
If IL-2 exposure upregulates miRNA-146a in vivo differ-
ences might be expected between naïve and memory T
cell subsets in their expression of miRNA-146a. However
this might be modulated by exposure to homeostatic IL-7
and IL-15, which could theoretically act to respectively
suppress or enhance miR-146a in both naïve and memory
CD8+ T cells. Previous studies have indicated that
miR-146a levels are upregulated in CD8+ T cell mem-
ory subsets [10,24]. To confirm this, and to investigate
the strength of miR-146a modulation in CD8+ T cell
subsets in vivo relative to other microRNAs, we carried
out micro-array analysis on sorted CD8+ T cell subsets.
Human CD8+ T cells were sorted ex vivo to ≥98% purity
from 3 healthy donors into the following subsets: naïve
(N = CCR7+, CD45RA+, CD45RO-), central memory
(Tcm=CCR7+, CD45RA-, CD45RO+), effector memory
(Tem =CCR7-, CD45RA-, CD45RO+) and effector mem-
ory CD45RA + (TemRA =CCR7-, CD45RA+, CD45RO-).
The 3 donors were selected from a wider pool of donors
to select for those with high proportions of N and Tcm
cells as we wanted to examine whether the earliest
events of antigen exposure were capable of modulating
miRNA-146a expression in early memory cells compared
to naïve cells.
We analysed the expression of miRNAs in N, Tcm and
Tem CD8+ T cell subsets using GeneChip miRNA Arrays








































ibited if IL-7 is also present. (A) Naïve T cells were cultured in the
8 days later cells were harvested and assessed for miR-146a expression
an individual donor, n = 3 or 4. Statistical significance was analysed
) with Tukey’s multiple comparison correction applied. Results with a
- D) Graphs showing % positive cells for CCR7+/CD45-RA+, CD28+ or
ne donor, n = 3.
Table 1 P values for miRNAs significantly differentially
expressed when comparing naïve to Tcm or Tem subsets
miRNAs up-regulated with differentiation
Tcm-naive Tem-naive Tem-Tcm
hsa-miR-146a 0.010 0.075 0.447
hsa-miR-221 0.023 0.130 0.737
hsa-miR-222 0.023 0.056 0.912
hsa-miR-23a 0.030 0.008 0.773
hsa-miR-24 0.046 0.005 0.413
hsa-miR-15a 0.742 0.041 0.457
hsa-miR-22 0.521 0.043 0.532
hsa-miR-28-5p 0.668 0.044 0.518
hsa-miR-663 0.340 0.034 0.600
miRNAs down-regulated with differentiation
Tcm-naive Tem-naive Tem-Tcm
hsa-miR-181a 0.006 0.006 0.800
hsa-miR-874 0.013 0.006 0.929
hsa-miR-92a 0.014 0.013 0.983
hsa-miR-378 0.015 0.015 0.973
hsa-miR-151-5p 0.015 0.005 0.651
hsa-miR-502-3p 0.015 0.152 0.518
hsa-miR-181b 0.021 0.040 0.936
hsa-miR-320d 0.022 0.009 0.912
hsa-miR-181c 0.022 0.034 0.976
hsa-miR-146b-3p 0.023 0.012 0.951
hsa-miR-342-3p 0.027 0.059 0.929
hsa-miR-1271 0.028 0.619 0.457
hsa-miR-146b-5p 0.032 0.093 0.902
hsa-miR-324-3p 0.038 0.362 0.651
hsa-miR-1275 0.040 0.609 0.518
hsa-miR-194 0.044 0.072 0.975
hsa-miR-342-5p 0.048 0.146 0.903
hsa-miR-20b 0.052 0.038 0.981
hsa-miR-192 0.157 0.034 0.814
hsa-miR-31 0.950 0.009 0.167
p values are shown for miRNAs that were statistically significantly up or down
regulated when comparing naïve cells to either the Tcm or Tem subsets using
Affymetrix miRNA microarrays.
Figures in bold represent p values <0.05.
Sheppard et al. Journal of Translational Medicine 2014, 12:292 Page 6 of 11
http://www.translational-medicine.com/content/12/1/292expressed overall in these subsets of CD8+ T cells. 85
miRNAs were detected in all 3 subsets, using a normalised
log2 fluorescence value of ≥ 4.0 across all 3 donors as our
threshold for expression (see Additional file 1: Table S1).
Using the same criteria to detect miRNAs expressed in
any subset, 112 miRNAs were expressed (see Additional
file 2: Table S2). Our analysis therefore confirms that a
limited subset of the miRNAs tested (13.2%) are expressed
in human CD8+ T cells and that there is differential
expression of specific miRNAs between CD8+ T cell
subsets. We found 29 miRNAs that are differentially
expressed between T cell subsets with statistical signifi-
cance (p value <0.05, see Table 1). Unsupervised clustering
(data not shown) suggests that naïve CD8+ T cells from
different individual donors are more similar to each other
than to memory T cell subsets from the same donor. Tcm
and Tem do not cluster as discrete subsets which suggest
that there is more of a continuum between these subsets.
Interestingly there were no statistically significant differ-
ences observed between Tcm and Tem subsets. This also
reflects high inter-donor variability.
Given the similar profiles in the naïve CD8+ T cells of
all 3 donors, we next asked which miRNAs showed the
largest differences between naïve cells and either of the
memory subsets i.e. which had been most strongly and
consistently modulated by a history of antigen exposure.
There were 9 statistically significant up-regulated miRNAs
when comparing naïve cells to one or both of the memory
subsets with the most significant hit being miR-146a
(when comparing naïve to Tcm subsets - see Table 1). Up-
regulation was confirmed by RT-PCR in four new donors
for each of the miRNAs that we validated in this way
(namely miR-22, −24 and -146a) (see Figure 4A - TemRA
cells were also included in this analysis). The trend in
increased expression with differentiation extended to
the TemRA subset in which miRNA expression was
significantly higher than in the naïve subset in each
case. However, due to high donor variability statistical
significance was not achieved when comparing naïve
cells to the Tcm or Tem subsets. Notably the RT-PCR
results indicate that expression levels of miR-146a were
4x and 50 x higher overall than the expression levels of
miR-24 and miR-22 respectively (data not shown).
20 miRNAs were statistically significantly down-regulated
when comparing N cells to one or both of the memory
subsets (see Table 1). As observed with the up-regulated
miRNAs there tended to be a trend toward down-
regulation of these miRNAs across both memory subsets.
Again down-regulation was confirmed by RT-PCR in four
new donors for each of the miRNAs we validated in
this way (miR-31, −92a, −181, −342-3p and −378, see
Figure 4B). Due to strong inter-donor variability statis-
tical significance was only achieved in 2 out of the 5
miRNAs tested. However, in each case there was adefinite downward trend in expression over the memory
T cell subsets compared to the naïve subset which tended
to extend to the TemRA subset also. miR-31 exhibited a
slightly different expression pattern with levels in the Tcm
subset being more similar to the naïve subset than to
the Tem subset (in both microarray and RT-PCR exper-
iments). miR-181 also showed a unique profile with
significant up-regulation of expression in TemRA cells
compared to Tcm cells in all 4 donors tested. Collect-
ively these data show that a limited number of miRNAs
** *
miR-22                                                  miR-24                                                  miR-146a
**
miR-342-3p                                          miR-378
*




Figure 4 Specific miRNAs are differentially expressed in CD8+ T cell subsets. The expression levels of nine miRNAs identified by microarray
analysis as being significantly differentially expressed between sorted naïve (N), central memory (CM) and effector memory (EM) T cell subsets
from 3 healthy humans donors were validated in a further 3 or 4 new donors by RT-PCR. Panel (A) shows miRNAs which were up regulated and
(B) shows miRNAs which were down regulated when comparing naïve to Tcm cells in microarray experiments. Each data point represents the
average of triplicates from an individual donor and is expressed relative to levels in naïve cells which are set to 1. Statistical significance was analysed
using GraphPad Prism software on non-normalised expression data using the Friedman test (on paired, non-parametric data) with Dunn’s multiple
comparison correction applied. Results with a p value <0.05 were considered to be statistically significant. * = p <0.05; ** = p <0.01.
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T cell subsets and are likely to be involved in their dif-
ferentiation status.
In order to assess the effect of IL-7 on miR-146a
expression in ex vivo memory cells, CD45-RO+ cells
were cultured in the presence of IL-7 for 28 days. In this
situation miR-146a expression was retained, if not
enhanced, compared to the expression levels detected in
uncultured ex vivo memory cells (Figure 5A). We there-
fore examined whether miRNA-146a expression becameconstitutive following exposure of naive cells to IL-2, or
whether continued signalling through CD122 was required
to maintain miRNA-146a expression in these cells. Naïve
cells exposed to IL-2 for 14 days were transferred into
either IL-7 or IL-15 for a further 7 days and miR-146a
expression was assessed (Figure 5B). There was a statisti-
cally significant drop in miR-146a expression when cells
were moved from IL-2 and into IL-7. However, if the cells
are moved into IL-15 expression levels remain high. These









































N         RO+  N         RO+
Ex vivo          IL-7 28 days
Figure 5 miR-146a expression is modulated by cytokine exposure in naïve cells but constitutive in memory cells. (A) The relative expression
of miR-146a was assessed by RT-PCR in freshly purified uncultured ex vivo memory cells or memory cells that had been cultured for 28 days in the
presence of 10 ng/ml IL-7. Each data point represents the average of triplicates from an individual donor, n = 2 or 3. (B) Naïve T cells were cultured in
the presence of IL-2 or IL-7 for 14 days and then either maintained in the same cytokine or transferred into IL-7 or IL-15 for a further 7 days, all at 10 ng/ml.
Cells were harvested and assessed for miR-146a expression levels by RT-PCR. Each data point represents the average of triplicates from an
individual donor, n = 4. Statistical significance was analysed using GraphPad Prism software using one way ANOVA test with Bonferroni’s
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Figure 6 CCR7, FADD and TRAF6 are targets of miR-146a. Naïve
CD8+ or CD8+/CD4+ T cells were nucleofected with either miR-146a
mimic or scrambled control. After 48 hours culture in 10 ng/ml IL-7
cells were harvested and either (A) subjected to RT-PCR analysis to
assess expression of putative targets of miR-146a namely CCR7, FADD
and TRAF6 or (B) PCR was performed to analyse for the presence of
various CD45 isoforms in cells following nucleofection. (A) Each bar
represents the average of triplicates from three separate experiments
and is expressed relative to the expression levels for each gene in cells
nucleofected with the scrambled control (con) which is set to 1. Error
bars represent standard deviation. A paired student’s t test was used to
assess significance on non-normalised data * = p <0.05; ** = p <0.01.
(B) Following CD45 specific cDNA synthesis and PCR, samples were
visualised on an agarose gel. Lane 1 = scrambled control, lane
2 = miR-146a mimic. As a comparison CD45 isoforms present in
either CD45RO +memory cells or ex vivo naïve were also assessed
(lanes 3 and 5 respectively). Lane 4 = DNA ladder.
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levels of miR-146a expression. Conversely ex vivo CD8+
memory cells cultured for 21 days in IL-7 alone retain high
levels of miR-146a expression (Figure 5A). This suggests
that at some point in the differentiation process miR-146a
expression becomes constitutively expressed.
CCR7, FADD and TRAF6 are targets of miR-146a
As miR-146a expression correlated with a memory pheno-
type in both ex vivo and in vitro cultured cells we next
asked if miR-146a expression alone is sufficient to drive
a memory phenotype. To answer this we nucleofected
naïve T cells with a miR-146a mimic and assessed the
expression of cell surface memory markers (CD45RA,
CD45RO and CCR7) by FACS. Cellular uptake of
fluorescently-labelled control reagents suggested high
uptake (>95%) of the mimic at 48 hours post-nucleofection
(data not shown). However, using flow cytometry we
observed no detectable effect on cell surface memory
markers at this time point (data not shown). This was
possibly due to the time of sampling as an analysis of
CCR7 mRNA expression did suggest a significant down
regulation in expression at 48 hours (see Figure 6A). In
addition TRAF6 expression, a previously validated target
for miR-146a [23,25], was significantly down regulated
at 48 hours post-nucleofection (Figure 6A). We also
observed down-regulation in the expression levels of
FADD mRNA, another predicted target of miR-146a
[24]. We assessed CD45 isoform expression at the mRNA
level (Figure 6B). However, CD45 isoform expression was
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and remained similar to those isoforms detected in ex vivo
naïve cells rather than those present in purified ex vivo
memory cells. These results suggest that over-expression
of miR-146a alone may not be sufficient to drive a cell
towards a memory phenotype. Alternatively it could be
that prolonged expression by miR-146a is required which
could not be achieved using this experimental system.
Discussion
We find that miR-146a is highly expressed in cells cul-
tured in vitro in the presence of IL-2 or IL-15, even in
the absence of a TCR stimulus. In addition, expression
of this microRNA correlates with a cell surface memory
phenotype in vitro and in ex vivo cells. Interestingly,
miR-146a expression is suppressed in the presence of
IL-7. Our results therefore show that miRNA expression
can be significantly affected by the presence of cytokines
alone. This has implications when designing expansion
protocols for T cells for use in immunotherapy.
There have been some recent reports indicating that the
expression of other microRNAs appears to be influenced
by cytokines [11,26-28]. However, miR-182 in mouse CD4+
T cells for example, requires both a TCR and IL-2 to be
induced; IL-2 alone was insufficient [26]. Expression of
miR-182 drops 4 days post stimulation. In concordance
with that result we did not observe up-regulation of miR-
182 in our array experiments on stimulated cells exposed
to IL-2 for 28 days. Rapid induction of miR-146a has been
shown in human monocytes in response to LPS and vari-
ous microbial components (expression was induced within
hours and assessed up to 14 hours post stimulation) [29].
miR-146a has also been shown to be rapidly induced in re-
sponse to IL-1β in human lung alveolar epithelial cells (ex-
pression was induced within hours and assessed up to
24 hours post stimulation) [30]. However, to our know-
ledge this paper represents the first report to show signifi-
cant modulation of expression of a microRNA in T cells by
prolonged exposure to cytokine alone. miR-146a has also
been reported to be induced post a TCR stimulus [23-25]
in T cells but we did not observe this in our experiments
(data not shown). However we note that our data agrees
with data reported for primary human CD4+ cells [24]
where up-regulation of miR-146a was only observed at be-
tween 12–14 days post TCR stimulation. Our data suggest
that TCR signalling is not causative for miR-146a expres-
sion and that it is possibly the IL-2 produced by T cells fol-
lowing TCR stimulation that up-regulates miR-146a.
miR-146a is emerging as a critical regulator of both the
innate and adaptive immune systems [31]. Its function in
T cells appears to be to regulate TCR-driven NFkB activa-
tion by targeting the signal transducers TRAF6 and
IRAK1, such that T cells in mice lacking miR-146a are
hyperactive [25]. More recently it has been implicated inT cell differentiation [23] which is in concordance with
our data. Although nucleofection utilising a miR-146a
mimic and human naïve CD8+ cells was not sufficient to
drive a full memory phenotype we did observe down-
regulation of CCR7 and TRAF6 mRNA comparable to
other recent observations [23]. As CCR7 is not predicted
to be a direct target of miR-146a this is likely to be an
indirect effect. In addition we note that ex vivo Tcm which
are CCR7+ and Tem which are CCR7- appear to express
similar levels of miR-146a. Nevertheless the reductionist
approach of nucleofection suggests that one component
of CCR7 modulation is miR-146a expression. TRAF6 has
been implicated in the generation of memory cells in mice
[32]. As TRAF6 has been shown to be a direct target for
miR-146a [23,25] this supports the idea that miR-146a
is involved in T cell memory formation or function.
However, further experimentation with sustained over-
expression of miR-146a will be required to more fully
examine the role of this microRNA in T cell memory.
Our nucleofection results also validated FADD as
another potential direct target for miR-146a in line with
other recent observations [24]. FADD is an adaptor
protein involved in FAS-mediated apoptosis pathway.
However, we found no correlation between miR-146a
expression and a reduction in apoptosis in our naïve T
cells cultured in IL-2 (data not shown), which is in con-
cordance with the findings of others [23].
Our results suggest that both IL-15 and IL-2 can drive
miR-146a expression whilst IL-7 does not. IL-2, IL-7 and
IL-15 share the CD132 subunit in their receptors but
only IL-2 and IL-15 share the CD122 receptor subunit.
This suggests that signalling via CD122, the shared
receptor chain common to both of these cytokines, may
be driving expression of miR-146a. Concomitant with
increased expression of miR-146a we also observed a
move towards a cell-surface memory phenotype even in
the absence of a TCR stimulus. The effect is less marked
than in the presence of a TCR and we hypothesise that
both miR-146a expression and cell division are required
to achieve a memory phenotype. It is interesting to note
that signalling via CD122 has been implicated in T cell
memory development [33] and further supports the
hypothesis that miR-146a is involved in formation of a
memory phenotype. The fact that IL-7 appears to inhibit
the IL-2 or IL-15 driven upregulation of miR-146a indicates
that there may be competition for the CD132 subunit
shared by all three cytokines, as has been suggested previ-
ously [34]. We note that miR-146a expression is somewhat
delayed in cells exposed to IL-2 in the presence of a TCR
stimulus compared to its absence (compare Figure 1E with
Figure 2). CD25 is the alpha chain of the IL-2 receptor,
expression of which has been shown to be up-regulated for
a number of days following a TCR stimulus [35]. CD25 up-
regulation may interfere with the CD122 driven signalling
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up-regulation would not occur in cells exposed to IL-2 in
the absence of a TCR stimulus, and this may explain the
more rapid expression of miRNA-146a in these cells.
A new T cell subset, stem cell-like memory T cells
(Tscm), has recently been identified [13]. It was reported
that naïve T cells expanded in the presence of IL-15 and
IL-7 retain an early stem cell memory phenotype i.e.
CD45RA + CD45R0 + CD62L + CCR7 + CD95+ [19]. The
presence of IL-7 was found to be unique in its ability to
instruct the T cells to a Tscm phenotype, while IL-15 and
CD28 co-stimulation appeared to be critical to optimum
expansion of the cells. Similar to our observations it was
reported that expansion in the presence of IL-2 or IL-15
drive a more memory-like phenotype [19]. In combination
with our results we propose that the presence of IL-7 is
required to inhibit the expression of miR-146a and
therefore promote an early stem cell phenotype. There-
fore expression of miR-146a may be a critical molecular
modulator underlying the generation of the optimum T
cell for use in immunotherapy.
Our microarray studies on ex vivo CD8+ T cell memory
subsets confirms a correlation between miR-146a expres-
sion and a cell surface memory phenotype as has been
observed by others [23-25]. The array data also showed
that there is differential expression of 112 miRNAs in the
three CD8+ T cell subsets we examined. As each miRNA
can affect multiple target genes and a single gene can be
targeted by multiple miRNAs [36] this is likely to affect
subsequent gene expression and affect subset function.
The number of miRNAs we identified is similar to that
observed in another study using a RT-PCR array approach
[10]. Our data expands this earlier data set and helps to
define the miRNA fingerprint present in human CD8+
memory subtypes. Up or down-regulation of individual
miRNA expression was confirmed in each case where
RT-PCR was used to validate microarray results. Although
results were not always statistically significant this reflects
high levels of inter-donor variability as has been observed
previously [10]. In general the trend of expression was
consistent across the 4 subsets tested i.e. increasing or de-
creasing progressively from naive through to Tem subsets.
Conclusion
In conclusion we show that expression of miR-146a and
cell surface memory phenotype is influenced by the cyto-
kine environment in vitro, independent of an activating
TCR. Our array data helps to refine a miRNA expression
fingerprint that defines specific human memory CD8+ T
cell subsets to which in vitro cultured cells can be com-
pared. These results have implications to studies designed
to assess the function of miR-146a. In addition they are
informative to the design of protocols used to expand
CD8+ T cells for immunotherapy.Additional files
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